环磷酰胺治疗原发性硬化性胆管炎的疗效观察

程鹏; 姚建宁; 王春峰

doi:10.3969/j.issn.1001-5256.2013.12.014

环磷酰胺治疗原发性硬化性胆管炎的疗效观察

DOI: 10.3969/j.issn.1001-5256.2013.12.014

郑州大学第一附属医院消化内科

详细信息

中图分类号: R575.7
计量
- 文章访问数: 2821
- HTML全文浏览量: 21
- PDF下载量: 571
- 被引次数: 0
出版历程
- 收稿日期: 2013-01-16
- 出版日期: 2013-12-20

Clinical efficacy of cyclophosphamide in treatment of primary sclerosing cholangitis

Department of Gastroenterology, The First Hospital of Zhengzhou University

摘要

摘要: 目的探讨环磷酰胺治疗原发性硬化性胆管炎（PSC）的临床疗效。方法选择2004年1月-2012年12月在本院消化内科治疗的24例PSC患者作为观察对象,随机分为观察组13例和对照组11例,对照组常规应用熊去氧胆酸进行治疗,观察组应用熊去氧胆酸和环磷酰胺进行治疗,两组患者治疗4周后,比较两组患者的临床疗效、胆红素的变化及用药后的不良反应。计数资料采用Fisher确切概率法,计量资料采用独立样本的t检验和配对样本的t检验进行分析。结果对照组的有效率为45.45%,观察组的有效率为84.62%,观察组明显高于对照组（P=0.0489）;观察组与对照组相比,治疗后TBil以及DBil改善明显,两组比较差异有统计学意义（t=12.45,P<0.001;t=5.60,P<0.001）。对照组治疗后的不良反应发生率为18.18%,观察组的不良反应发生率为23.08%,观察组的不良反应的发生率略高于对照组,差异无统计学意义（P=0.741）。结论环磷酰胺治疗PSC临床疗效明显,不良反应的发生率在患者耐受范围内,故可在临床治疗中试用。
- 环磷酰胺 /
- 胆管炎,硬化性
Abstract: Objective To investigate the clinical efficacy of cyclophosphamide in the treatment of primary sclerosing cholangitis ( PSC) .Methods Twenty-four patients with PSC who received treatment in the department of gastroenterology in our hospital from January 2004 to December 2012 were selected as subjects and divided into observation group ( n = 13) and control group ( n = 11) . The control group was treated with ursodesoxycholic acid, while the observation group with ursodesoxycholic acid plus cyclophosphamide. After four weeks of treatment, clinical outcome, changes in serum bilirubin levels, and adverse reactions were compared between the two groups. Categorical data were analyzed by Fisher exact probability test, and continuous data by independent-samples t test and paired-samples t test. Results Compared with the control group, the observation group had a significantly higher response rate ( 84. 62% vs 45. 45%, P = 0. 0489) , significantly more improvements in serum total and direct bilirubin levels ( t = 12. 45, P < 0. 001; t = 5. 60, P < 0. 001) , and a nonsignificantly higher incidence of adverse reactions ( 23. 08% vs 18. 18%, P = 0. 741) . Conclusion Cyclophosphamide has significant clinical efficacy and tolerable incidence of adverse events in the treatment of PSC, so it is worthy of application in clinical treatment.
- cyclophosphamide /
- cholangitis, sclerosing

HTML全文

参考文献(13)

[1]BAMBHA K, KIM WR, TALWALKAR J, et al.Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community[J].Gastroenterology, 2003, 125 (5) :1364-1369.

[2]TAKIKAWA H, MANABE T.Primary sclerosing cholangitis in Japan-analysis of 192 cases[J].J Gastroenterol, 1997, 32 (1) :134-137.

[3]ARENAS-GAMBOA AM, BEARSS JJ, HUBBARD GB, et al.Sclerosing cholangitis in baboons (Papio spp) resembling primary sclerosing cholangitis of humans[J].Vet Pathol, 2012, 49 (3) :524-527.

[4]QU Y, XU YM, LU LG.Current progress in understanding of cholestasis and autoimmune liver diseases-Meeting review about 1st symposium on cholestasis and autoimmune liver disease[J].J Clin Hepatol, 2011, 27 (2) :222-225. (in Chinese) 曲颖, 徐铭益, 陆伦根.胆汁淤积和自身免疫性肝病研究进展暨“第一届胆汁淤积和自身免疫性肝病专题学术研讨会”纪要[J].临床肝胆病杂志, 2011, 27 (2) :222-225.

[5]POUPON R.Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases:an overview of their mechanisms of action[J].Clin Res Hepatol Gastroenterol, 2012, 36 (Suppl 1) :s3-s12.

[6]ZHAO YJ, SUN JY.The therapeutic effect of ursodeoxycholic acid capsules in patients with primary biliary cirrhosis[J].J Clin Hepatol, 2010, 26 (4) :432-433. (in Chinese) 赵艳娟, 孙吉莹.熊去氧胆酸 (优思弗) 治疗原发性胆汁性肝硬化的临床疗效观察[J].临床肝胆病杂志, 2010, 26 (4) :432-433.

[7]LINDOR KD, KOWDLEY KV, LUKETIC VA, et al.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis[J].Hepatology, 2009, 50 (3) :808-814.

[8]IBRAHIM SH, LINDOR KD.Current management of primary sclerosing cholangitis in pediatric patients[J].Pediatr Drugs, 2011, 13 (2) :87-95.

[9]STANKIEWICZ JM, KOLB H, KARNI A, et al.Role of immunosuppressive therapy for the treatment of multiple sclerosis[J].Neurotherapeutics, 2013, 10 (1) :77-88.

[10]OH DC, NG TM, HO J, et al.Systemic lupus erythematosus with concurrent protein-losing enteropathy and primary sclerosing cholangitis:a unique association[J].Lupus, 2006, 15 (2) :102-104.

[11]CHEN M, LI H, LI XY, et al.Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy:a multicenter randomized controlled trial[J].Am J Med Sci, 2010, 339 (3) :233-238.

[12]MALVICINI M, PICCIONI F, BAYO J, et al.Chemoimmunotherapy for advanced gastrointestinal carcinomas:A successful combination of gene therapy and cyclophosphamide[J].Oncoimmunology, 2012, 1 (9) :1626-1628.

[13]RAZA M, ALGHASHAM AA.Desferrioxamine protects against toxic damage to liver and kidney induced by cyclophosphamide[J].Int J Health Sci (Qassim) , 2011, 5 (2 Suppl 1) :15-17.

施引文献

资源附件(0)

访问统计